🚨 #ESMO26 | Elfe-D + pumitamig across solid tumors
First clinical data beyond lung cancer for the B7-H3 ADC elfetabart drozuntecan + PD-L1×VEGF-A bsAb pumitamig!
📊 N=139 efficacy-evaluable: uORR 48.9% | cORR 39.6% | DCR 87.8%
👀 Melanoma (n=26): uORR 30.8% | cORR 26.9% | DCR 80.8%
Safety appeared manageable, with mainly G1–2 GI/hematologic TRAEs, no DLTs or treatment-related deaths, and 2 investigator-reported ILD cases 👍🏼
One question: is the activity driven by the IO, the antiangiogenic effect, or a synergy between the two?? 🤔
@OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma
231 浏览 · 5 赞 · 5 转发 · 1 回复
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.org- Sid The Bear@OverboughtWatch
@MarioBalsaMD Hi do you know when the Moderna presentation is and will you post the results?
来源：Mario Balsa · x.com